TY - JOUR
T1 - Fetal programming of COVID-19
T2 - May the barker hypothesis explain the susceptibility of a subset of young adults to develop severe disease?
AU - Gerosa, Clara
AU - Faa, G.
AU - Fanni, D.
AU - Manchia, M.
AU - Suri, J. S.
AU - Ravarino, A.
AU - Barcellona, D.
AU - Pichiri, G.
AU - Coni, P.
AU - Congiu, T.
AU - Piras, M.
AU - Cerrone, G.
AU - Cau, F.
AU - Ledda, F.
AU - Aimola, V.
AU - Coghe, F.
AU - Porcu, M.
AU - Cau, R.
AU - Orru', G.
AU - Van Eyken, P.
AU - La Nasa, G.
AU - Castagnola, M.
AU - Marongiu, F.
AU - Saba, L.
N1 - Publisher Copyright:
© 2021 Verduci Editore s.r.l. All rights reserved.
PY - 2021
Y1 - 2021
N2 - The risk stratification of young adults between subjects who will develop a mild form COVID-19 and subjects who will undergo a severe disease remains inaccurate. In this review, we propose that the Barker hypothesis might explain the increased susceptibility to severe forms of COVID-19 in subjects who underwent intrauterine growth restriction (IUGR). In this paper evidence indicating an association between a low birth weight and an adult phenotype which might favor a severe outcome of SARS-CoV-2 infection are presented: lower lung functional capacity; increased respiratory morbidity; changes in fibrinogen and Factor VII serum levels and dysregulation of the hemostasis and thrombosis system; acquisition of a pro-thrombotic phenotype; low nephron number, with decreased ability to sustain renal function and increased renal morbidity; heart remodeling, with a less efficient cardiac function; endothelial dysfunction, a risk factor for the insurgence of the multiple organ failure; remodeling of arteries, with changes in the elastic properties of the arterial wall, predisposing to the insurgence and progression of atherosclerosis; dysfunction of the innate immune system, a risk factor for immune diseases in adulthood. These data suggest that young and adult subjects born too small (IUGR) or too early (pre-terms) might represent a subgroup of "at risk subjects", more susceptible toward severe forms of COVID-19. Given that LBW may be considered a surrogate of IUGR, this phenotypic marker should be included among the indispensable clinical data collected in every patient presenting with SARSCOV- 2 infection, irrespectively of his/her age.
AB - The risk stratification of young adults between subjects who will develop a mild form COVID-19 and subjects who will undergo a severe disease remains inaccurate. In this review, we propose that the Barker hypothesis might explain the increased susceptibility to severe forms of COVID-19 in subjects who underwent intrauterine growth restriction (IUGR). In this paper evidence indicating an association between a low birth weight and an adult phenotype which might favor a severe outcome of SARS-CoV-2 infection are presented: lower lung functional capacity; increased respiratory morbidity; changes in fibrinogen and Factor VII serum levels and dysregulation of the hemostasis and thrombosis system; acquisition of a pro-thrombotic phenotype; low nephron number, with decreased ability to sustain renal function and increased renal morbidity; heart remodeling, with a less efficient cardiac function; endothelial dysfunction, a risk factor for the insurgence of the multiple organ failure; remodeling of arteries, with changes in the elastic properties of the arterial wall, predisposing to the insurgence and progression of atherosclerosis; dysfunction of the innate immune system, a risk factor for immune diseases in adulthood. These data suggest that young and adult subjects born too small (IUGR) or too early (pre-terms) might represent a subgroup of "at risk subjects", more susceptible toward severe forms of COVID-19. Given that LBW may be considered a surrogate of IUGR, this phenotypic marker should be included among the indispensable clinical data collected in every patient presenting with SARSCOV- 2 infection, irrespectively of his/her age.
UR - http://www.scopus.com/inward/record.url?scp=85116085179&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116085179&partnerID=8YFLogxK
U2 - 10.26355/eurrev_202109_26810
DO - 10.26355/eurrev_202109_26810
M3 - Article
C2 - 34604981
AN - SCOPUS:85116085179
SN - 1128-3602
VL - 25
SP - 5876
EP - 5884
JO - European Review for Medical and Pharmacological Sciences
JF - European Review for Medical and Pharmacological Sciences
IS - 18
ER -